CG Oncology News and Activities
Presence
CG Oncology develops cancer treatments for bladder disease. Its products and services include oncolytic immunotherapies and clinical development programs for hospitals, doctors, and patients.
CG Oncology products and services overview:
- Bladder cancer therapy
- Oncolytic immunotherapy
- Cancer drug development
- Clinical trial programs
Revenue: ~$0 million
Employees: 120
Headquarters: Irvine, United States (USA)
CG Oncology is one of the...
CG Oncology is a company listed under the stock ticker CGON (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at CG Oncology
- Arthur Kuan, Chief Executive Officer, Chairman of the Board and Pr...
- Brian Liu, Director
- Christina Rossi, Director
Popular executive movements at CG Oncology
- Arthur Kuan who was Chief Executive Officer and Chairman of the Board, becomes Chief Executive Officer, Chairman of the Board and President (posted on May 27 2026).
- Ambaw Bellete, President and Chief Operating Officer, will leave the company on Jun. 30, 2026 (posted on May 27 2026).
- Jim DeTore, who was Interim Principal Financial and Accounting Officer, is promoted to Chief Financial Officer (posted on April 16 2026).
Click here to view some more movements at CG Oncology
Create your alert
to follow the executive moves at CG Oncology.
Biotechnology
CG Oncology has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by CG Oncology
- CG Oncology to Present at Upcoming Investor Conferences in June | CG Oncology
- SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award | CG Oncology
- CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | CG Oncology
- CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC | CG Oncology
- CG Oncology to Present at Upcoming Investor Conferences in May | CG Oncology
- CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | CG Oncology
- CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference | CG Oncology
- CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | CG Oncology
- CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | CG Oncology
- CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference | CG Oncology
- View more press releases Close
Social media about CG Oncology
- CG Oncology on Wikipedia, Google News & Yahoo Finance
- CG Oncology on LinkedIn, X (Twitter) & YouTube
